Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
A phase 2 trial of Nemtabrutinib in chronic lymphocytic leukaemia, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) is a phase 2 interventional study registered as NCT04728893 by Merck Sharp & Dohme LLC, with 490 participants planned, started 2021-04-05 and due to reach its primary completion in 2029-01-04. Interventions recorded: Nemtabrutinib. Conditions listed: Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Shares Nemtabrutinib, Chronic lymphocytic leukaemia, Merck & Co. (MSD).
- TrialA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Shares Nemtabrutinib, Chronic lymphocytic leukaemia, Merck & Co. (MSD).
- TrialA Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Shares Nemtabrutinib, Merck & Co. (MSD).
- TrialA Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-
Shares Nemtabrutinib, Merck & Co. (MSD).
- TrialBELLWAVE-011